Literature DB >> 21144858

Impaired auditory and contextual fear conditioning in soman-exposed rats.

Mark C Moffett1, Mark K Schultz, Julia E Schwartz, Michael F Stone, Lucille A Lumley.   

Abstract

Exposure to soman (GD) can result in prolonged seizures and subsequent neuropathology in a variety of brain regions including the amygdala and hippocampus. Both regions are believed to play important roles in the development and expression of fear conditioning. The purpose of this experiment was to test these conditioning tasks as a possible behavioral correlate of the observed neuropathology. Male rats were exposed to GD (1.0 or 1.2×LD50) or saline followed with injections of atropine sulfate, the oxime HI-6 and diazepam. Fear conditioning was conducted on post-exposure day (PED) 8 followed by measuring freezing to contextual and auditory conditioned stimuli on PED 9 and 10 respectively. Contextual and auditory fear conditioning was severely impaired in both the 1.0×LD50 and 1.2×LD50 GD groups. Both GD groups spent less time freezing than controls when returned to the context in which conditioning occurred. The 1.0×LD50 and 1.2×LD50 groups had very low levels of freezing following presentation of the auditory conditioned stimulus. Neuronal fiber degeneration was present in the piriform cortex, thalamus, and amygdala in GD-exposed animals regardless of dose. The present study suggests that contextual and auditory fear conditioning is impaired in GD-exposed rats possibly due to neuropathology observed in the hippocampus, amygdala and thalamus.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144858     DOI: 10.1016/j.pbb.2010.11.022

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  11 in total

1.  Pathophysiological mechanisms underlying increased anxiety after soman exposure: reduced GABAergic inhibition in the basolateral amygdala.

Authors:  Eric M Prager; Volodymyr I Pidoplichko; Vassiliki Aroniadou-Anderjaska; James P Apland; Maria F M Braga
Journal:  Neurotoxicology       Date:  2014-08-20       Impact factor: 4.294

2.  Delayed midazolam dose effects against soman in male and female plasma carboxylesterase knockout mice.

Authors:  Erica Kundrick; Brenda Marrero-Rosado; Michael Stone; Caroline Schultz; Katie Walker; Robyn B Lee-Stubbs; Marcio de Araujo Furtado; Lucille A Lumley
Journal:  Ann N Y Acad Sci       Date:  2020-02-06       Impact factor: 5.691

3.  Age-Related Susceptibility to Epileptogenesis and Neuronal Loss in Male Fischer Rats Exposed to Soman and Treated With Medical Countermeasures.

Authors:  Brenda Marrero-Rosado; Franco Rossetti; Matthew W Rice; Mark C Moffett; Robyn B Lee; Michael F Stone; Lucille A Lumley
Journal:  Toxicol Sci       Date:  2018-07-01       Impact factor: 4.849

4.  Alpha-Linolenic Acid-Induced Increase in Neurogenesis is a Key Factor in the Improvement in the Passive Avoidance Task After Soman Exposure.

Authors:  Tetsade C B Piermartiri; Hongna Pan; Jun Chen; John McDonough; Neil Grunberg; James P Apland; Ann M Marini
Journal:  Neuromolecular Med       Date:  2015-04-29       Impact factor: 3.843

Review 5.  Acute and long-term consequences of exposure to organophosphate nerve agents in humans.

Authors:  Taiza H Figueiredo; James P Apland; Maria F M Braga; Ann M Marini
Journal:  Epilepsia       Date:  2018-08-29       Impact factor: 5.864

6.  Ketamine as adjunct to midazolam treatment following soman-induced status epilepticus reduces seizure severity, epileptogenesis, and brain pathology in plasma carboxylesterase knockout mice.

Authors:  Brenda M Marrero-Rosado; Marcio de Araujo Furtado; Erica R Kundrick; Katie A Walker; Michael F Stone; Caroline R Schultz; Donna A Nguyen; Lucille A Lumley
Journal:  Epilepsy Behav       Date:  2020-06-20       Impact factor: 2.937

7.  The recovery of acetylcholinesterase activity and the progression of neuropathological and pathophysiological alterations in the rat basolateral amygdala after soman-induced status epilepticus: relation to anxiety-like behavior.

Authors:  Eric M Prager; Vassiliki Aroniadou-Anderjaska; Camila P Almeida-Suhett; Taiza H Figueiredo; James P Apland; Franco Rossetti; Cara H Olsen; Maria F M Braga
Journal:  Neuropharmacology       Date:  2014-01-31       Impact factor: 5.250

8.  Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Carol E Green; Robert Swezey; Chun Yang; Felicia Qashu; Maria F M Braga
Journal:  J Pharmacol Exp Ther       Date:  2012-10-05       Impact factor: 4.030

9.  LY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.

Authors:  Eric M Prager; Taiza H Figueiredo; Robert P Long; Vassiliki Aroniadou-Anderjaska; James P Apland; Maria F M Braga
Journal:  Neuropharmacology       Date:  2014-09-06       Impact factor: 5.250

10.  Parameter optimization for automated behavior assessment: plug-and-play or trial-and-error?

Authors:  Laura Luyten; Natalie Schroyens; Dirk Hermans; Tom Beckers
Journal:  Front Behav Neurosci       Date:  2014-02-04       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.